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Introduction
At any point, approximately 10% of women and 7%
of men are estimated to be suffering from a depress-
ive disorder.1,2 Up to 30% of people suffer from a
depressive disorder at some point in their life;3 with
around 18% experiencing chronic symptoms.4
Research on major depressive disorder in secondary
care settings indicates that the longer-term use of
antidepressant medication is demonstrably bene-
ficial for those who experience recurrent depressive
disorder,5 or where there has been a prolonged,
ABSTRACT
This cross-sectional survey describes the clinical
characteristics of 92 patients from across 12 gen-
eral medical practices, in receipt of a long-term
repeat prescription of an antidepressant for the
treatment of depression. Psychiatric diagnoses
were determined using the Schedule for Clinical
Assessment in Neuropsychiatry. Fifty-three par-
ticipants (57.6%) failed to meet criteria for any
psychiatric diagnosis (95% confidence interval
(CI): 47.5–67.7%). Independentclinical assessments
based upon diagnoses and other clinical data
indicated that 26 (31.0%) participants (95% CI:
28.9–49.7%) had no clear clinical reason for con-
tinued receipt of an antidepressant. Reasons for
the continued use of antidepressants in this popu-
lation require further investigation.
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severe and disabling episode.6,7 Although evidence
exists to support the effectiveness of antidepressant
medication among primary care patients,8,9 little
is known regarding their actual longer-term clinical
use within general practice settings. We therefore
sought to describe theclinical characteristics ofpeople
receiving long-term prescriptions for antidepressant
drug treatments in primary care, and assess whether
such prescriptions were consistent with the contem-
porary evidence base and relevant clinical guidelines.
Method
Prior permission from the Tayside Research Ethics
Committee was obtained.
Sample
Twelve general medical practices (GMPs) in Tayside
were recruited from urban (7), semi-urban (4) and
rural (1) settings. A total of 1257 individuals aged
over 18 years and prescribed an antidepressant drug
for more than 18 months were identified from the
GMPs’ prescribing databases. This represented 1.8%
of the practice population (n = 69 037). A random
sample of 442 potential participants was obtained
after clinician-directed exclusions (for example, pre-
scription of antidepressant drug for chronic pain).
One hundred and twenty-three participants (27.8%)
opted in to thestudy.Twenty-eightwere subsequently
excluded for three reasons: withdrawal of consent
to participate (25), presence of significant cognitive
impairment (2), and no longer prescribed an anti-
depressant (1). Ninety-two people were eventually
interviewed.
Data collection
DSM-IV (Diagnostic and Statistical Manual of Men-
tal Disorders) and ICD-10 (International Classifi-
cation of Diseases) psychiatric diagnostic data were
collected using the SCAN (Schedules for Clinical
Assessment in Neuropsychiatry) structured interview
version 2.1.10 Standardised observer rating scales for
depression severity were completed (the HAM-D17
(Hamilton Depression scale) and MADRS (Montgomery–
A˚sberg Depression Rating Scale)), and a detailed case
note review was performed. In the absence of evidence-
based guidelines for this particular patient group, an
assessment of the appropriateness of a continued
prescription requires a clinical judgement. In order to
judge approriateness of prescribing, a general prac-
titioner (DB) and psychiatrist (KM) independently
examined data from case notes, DSM and ICD diag-
noses for both representative episodes, and current
health status, as well as symptom burden as quanti-
fied by the HAM-D17 and MADRS scores. Subse-
quently, they indicated whether, in their judgement,
current prescribing was ‘appropriate’, ‘inappropriate’,
‘neither’, or there was ‘insufficient information to
make a judgement’. Inter-rater agreement was then
calculated. Participants were also asked to indicate
their willingness to stop their antidepressant or
change the dose.
Analysis
Data were analysed with SPSS version 12.0, using
descriptive statistics and confidence intervals where
appropriate. Diagnoses were analysed by DSM-IV
criteria. Kappa coefficients were used to assess agree-
ment between raters.
Results
Sixty-one (66.3%) study participants were female
and 31 (33.1%) male. Mean age was 58 years (see
Table 1). There was no significant difference in age
between men and women; 29% received a tricyclic
Table 1 Demographic and clinical
characteristics
Characteristic (n = 92)
Sex n (%)
Female 61 (66.3)
Male 31 (33.7)
Mean age (years) 58.27
Percentage on tricyclic antidepressant 29
SCAN-derived current DSM-IV
diagnosis
n (%)
No psychiatric diagnoses 53 (57.6)
Phobias 29 (31.5)
Depressive disorder 27 (29.3)
Drug dependence (excluding
nicotine)
15 (16.3)
Sleep disorders 10 (10.9)
Psychosis 3 (3.3)
Other mood disorder 3 (3.3)
Anxiety 2 (2.2)
Obsessive-compulsive disorder
(OCD)
2 (2.2)
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antidepressant and 71% other types of antidepres-
sants.
The majority of participants (57.6%: 95% confi-
dence interval (CI) 47.5–67.7%) were found not to
meet criteria for any current DSM-IV diagnosis (see
Table 1). Anxiety-related diagnoses, including pho-
bias and obsessive-compulsive disorder (OCD), were
most common (35.9%: 95% CI 26.1–45.7%). Fewer
than one-third (29.3%) of participants met criteria
for a diagnosis of a depressive disorder; 13% of par-
ticipants had a major depressive disorder, 3% had
dysthymia, and 6% had bipolar depression. The mean
age of those with a DSM-IV diagnosis was 54.8 years
compared to 60.1 years for those with no psychiatric
diagnosis (P = 0.03).
Of the 53 people with no DSM-IV diagnosis, 41
(77.4%) also had no evidence of significant depress-
ive symptoms according to the HAM-D17. Similar
results were found using the MADRS: 35 (66.0%)
scored within the healthy population range (see
Table 2).
Clinician judgement of the
appropriateness of long-term
antidepressant therapy
Agreement between raters was high (k = 0.78). The
general practitioner (GP) rater judged 52 (62.7%)
people were receiving an antidepressant appropri-
ately and 29 (34.9%) inappropriately, compared to
51 (61.4%) and 29 (34.9%), respectively for the psych-
iatrist. Both clinicians agreed that 26 of the 83
patients (31.3%; 95% CI 19.3–43.3%) were receiving
an inappropriate drug treatment in the light of their
current and previous diagnoses and available clinical
data contained within the primary care case notes.
There was agreement that 47 participants (56.6%;
95% CI 45.9–67.3%) were appropriately receiving an
antidepressant.
Of the 26 adjudged to be inappropriately receiving
an antidepressant, none were found to have severe
depression on the HAM-D17 or MADRS, and just one
had moderate depression (see Table 2). Nineteen
(73.1%) did not meet criteria for any relevant
DSM-IV diagnosis. It was considered possible that
some participants might have met criteria for a
diagnosis of recurrent depressive disorder. DSM-IV
does not allow for this diagnosis, but ICD-10 does.
However, examination of the SCAN data revealed
that none of these participants met criteria for such
an ICD-10 diagnosis.
Attitudes among those on ‘inappropriate’
prescriptions
Thirteen (50.0%) of the 26 people considered to be
receiving an antidepressant without strong clinical
indication, reported that, if asked by their GP, they
would be likely to stop taking their antidepressant.
Nineteen (73.1%) said that they would agree to
change their antidepressant, 13 (50.0%) would in-
crease the dose, and 15 (60.0%) would agree to a
reduction in the dose.
Table 2 HAM-D17 and MADRS scores
All participantsa
(n = 89)
Participants with no
DSM-IV psychiatric
disorder (n = 53)
Participants agreed as
not requiring an
antidepressant (n = 26)
HAM-D17
Mean, n (95% CI) 7.4 (6.1–8.7) 4.5 (3.3–5.7) 5.1 (2.7–5.3)
No or minimal depression, n (%) 51 (57) 41 (77) 19 (73)
Mild depression, n (%) 28 (32) 11 (21) 7 (27)
Moderate depression, n (%) 10 (11) 1 (1.9) 0
Severe depression 0 0 0
MADRS
Mean n (95% CI) 9.5 (6.4–12.6) 5.7 (4.0–7.4) 6.5 (4.1–8.9)
Normal, n (%) 42 (47) 35 (66) 15 (57)
Mild depression, n (%) 32 (36) 17 (32) 10 (39)
Moderate depression, n (%) 15 (17) 1 (2) 1 (4)
Severe depression 0 0 0
a HAM-D17 and MADRS were not available for three participants.
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Discussion
The paucity of syndromal diagnoses and the absence
of significant depressive symptoms among a large
proportion of our sample may, of course, be due to
the effectiveness of the drug treatments themselves.
Current National Institute for Health and Clinical
Excellence (NICE) guidance, issued since this study
was conducted, recommends that maintenance treat-
ment should be re-evaluated, taking into account
age, co-morbid conditions, and other risk factors in
the decision to continue antidepressant treatment
beyond two years.11 Sinceour study found fewreasons
for continuation among a significant proportion of
patients at 18 months, it is likely that the figure would
be even higher at two years.
If approximately one-third of patients on long-
term antidepressant therapy in primary care have no
identifiable clinical justification for their prescrip-
tion, then cessation strategies may need to be con-
sidered. However, identifying potential candidates
for cessation may be problematic since the identi-
fying formal diagnoses and quantifying symptom
burden is time consuming.
This study has identified a potentially large popu-
lation of patients who may benefit from alteration,
or cessation, of their antidepressant therapy. This,
we believe, further strengthens the case for a chronic
disease-management approach to depression in pri-
mary care.12 The challenge to clinical practice is to
ensure that patients on long-term antidepressant
therapy benefit from regular and structured assess-
ments. This would allow patients and practitioners
to make rational decisions regarding the need for
continuation of their medication.
Study strengths and limitations
To our knowledge, this is the first study that has used
a structured psychiatric diagnostic assessment (SCAN)
together with validated symptom burden rating scales
to establish robust diagnoses and symptom burden
among patients prescribed long-term antidepressant
medication in primary care.
We recruited from 12 volunteer practices in a single
region rather than a national sample. Our response
rate of 21% was perhaps influenced by the insistence
of the local ethics committee that we permit clin-
ician ‘screening’ at the level of the GMP and that we
should use an ‘opt-in’ procedure that has the poten-
tial to leadtosamplingbias.13 Inourstudy, individuals
with no psychiatric morbidity and who were amen-
able to changes in treatment may have been more
likely to participate in the study. GPs believed that
complex and patient-specific factors relating to past
clinical history and current social/clinical circum-
stances may appropriately account for some pre-
scribing decisions. We acknowledged this possibility
through independent examination of notes along-
side all available diagnostic and symptom reporting.
However, consideration of such idiosyncratic factors
necessarily precludes the formulation of a priori
criteria, and draws on clinical judgement. This may
be regarded as both a strength and potential weak-
ness of the study.
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